Elicio Therapeutics (ELTX) Retained Earnings (2020 - 2026)
Elicio Therapeutics posted quarterly Retained Earnings of -$245.5 million for Q1 2026, down 19.58% year-on-year from -$305.3 million in Q1 2025, and down 5.06% on a QoQ basis from -$233.7 million in Q4 2025.
Elicio Therapeutics (ELTX) has 7 years of Retained Earnings data on file, last reported at -$245.5 million in Q1 2026.
- For the quarter ending Q1 2026, Retained Earnings fell 19.58% year-over-year to -$245.5 million; the trailing twelve-month figure through Mar 2026 stood at -$245.5 million (down 19.58% YoY), and the FY2025 full-year result was -$233.7 million, down 133426.86% from the prior year.
- Retained Earnings for Q1 2026 stood at -$245.5 million, down from -$233.7 million in the prior quarter.
- Across five years, Retained Earnings topped out at $302000.0 in Q3 2022 and bottomed at -$258.5 million in Q1 2023.
- The 5-year median for Retained Earnings is -$133.3 million (2023), against an average of -$130.4 million.
- The widest annual swing landed in 2022, when Retained Earnings soared 100.13%; it then sank 133426.86% in 2025.
- A 5-year view of Retained Earnings shows it stood at -$107.0 million in 2022, then soared by 99.82% to -$197000.0 in 2023, then climbed by 11.17% to -$175000.0 in 2024, then tumbled by 133426.86% to -$233.7 million in 2025, then fell by 5.06% to -$245.5 million in 2026.
- The last three Retained Earnings figures came in at -$245.5 million (Q1 2026), -$233.7 million (Q4 2025), and -$226.0 million (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Retained Earnings (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | -211.85 Mn |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | -153.89 Mn |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | 1.00 Bn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | -438.66 Mn |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | -279.00 Mn |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 14.59 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | 130.89 Mn |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 36.42 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | -24.89 Mn |
| 10 | Elicio Therapeutics | 217.63 Mn | 202.68 Mn | - | -245.50 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -245.50 Mn |
| Dec 31, 2025 | -233.67 Mn |
| Sep 30, 2025 | -226.00 Mn |
| Jun 30, 2025 | -215.87 Mn |
| Mar 31, 2025 | -205.31 Mn |
| Dec 31, 2024 | -175,000.00 |
| Sep 30, 2024 | -202,000.00 |
| Jun 30, 2024 | -238,000.00 |
| Mar 31, 2024 | -270,000.00 |
| Dec 31, 2023 | -197,000.00 |
| Sep 30, 2023 | -133.30 Mn |
| Jun 30, 2023 | -122.60 Mn |
| Mar 31, 2023 | -258.48 Mn |
| Dec 31, 2022 | -107.01 Mn |
| Sep 30, 2022 | 302,000.00 |
| Jun 30, 2022 | -238.50 Mn |
| Mar 31, 2022 | -229.40 Mn |
| Dec 31, 2021 | -103,000.00 |
| Sep 30, 2021 | -230.03 Mn |
| Jun 30, 2021 | -214.30 Mn |
| Mar 31, 2021 | -197.20 Mn |
| Dec 31, 2020 | -333,000.00 |